Point72 Asia (Singapore) Pte. Ltd. Intellia Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 4,739 shares of NTLA stock, worth $107,859. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,739Holding current value
$107,859% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
314Shares Held
89.3MCall Options Held
686KPut Options Held
599K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$250 Million2.16% of portfolio
-
Black Rock Inc. New York, NY9.11MShares$207 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$207 Million0.01% of portfolio
-
State Street Corp Boston, MA4.6MShares$105 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.21MShares$95.8 Million3.83% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.73B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...